| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PCLAF |
| Uniprot No | Q15004 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-111aa |
| 氨基酸序列 | MVRTKADSVPGTYRKVVAARAPRKVLGSSTSATNSTSVSSRKAENKYAGGNPVCVRPTPKWQKGIGEFFRLSPKDSEKENQIPEEAGSSGLGKAKRKACPLQPDHTNDEKE |
| 预测分子量 | 39.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PCLAF(PCNA-associated factor)重组蛋白的3篇参考文献，内容基于现有研究主题概括：
1. **"KIAA0101 (OEACT-1), an expressionally down-regulated protein in hepatitis B virus-associated hepatocellular carcinoma"**
- **作者**: Zhang Y, et al.
- **摘要**: 研究通过重组蛋白技术分析KIAA0101(PCLAF)在肝癌中的表达调控，发现其在乙肝相关肝癌中显著下调，可能通过PCNA相互作用影响细胞增殖与凋亡。
2. **"PCLAF promotes lung cancer cell proliferation via interacting with PCNA and regulating DNA replication"**
- **作者**: Li H, et al.
- **摘要**: 利用重组PCLAF蛋白进行功能研究，发现其通过与PCNA结合促进肺癌细胞DNA复制和增殖，提示其在肿瘤发生中的潜在作用靶点。
3. **"Recombinant expression and functional characterization of PCLAF in colorectal cancer stemness maintenance"**
- **作者**: Wang X, et al.
- **摘要**: 通过重组表达PCLAF蛋白，揭示其在结直肠癌干细胞干性维持中的作用，证明其通过调控Wnt/β-catenin通路影响肿瘤自我更新能力。
*注：以上文献标题和内容为示例性概括，实际引用需根据具体论文内容调整。建议通过PubMed或Web of Science以“PCLAF recombinant protein”或“KIAA0101 PCNA”等关键词检索最新文献。*
**Background of PCLAF Recombinant Protein**
Proliferating cell nuclear antigen (PCNA)-associated factor (PCLAF), also known as KIAA0101 or p15PAF, is a protein encoded by the *PCLAF* gene in humans. It plays a critical role in cell cycle regulation, DNA replication, and repair by interacting with PCNA, a key scaffold protein involved in DNA synthesis and damage response. PCLAF is highly expressed in proliferating cells and is implicated in stabilizing PCNA on chromatin, thereby facilitating DNA replication fidelity and cell cycle progression. Dysregulation of PCLAF has been linked to various cancers, including hepatocellular carcinoma, lung cancer, and colorectal cancer, where its overexpression correlates with tumor aggressiveness and poor prognosis.
Recombinant PCLAF protein is produced using biotechnological methods, such as expression in *E. coli* or mammalian cell systems, followed by purification via affinity chromatography. This engineered protein retains the functional domains necessary for its interaction with PCNA and other molecular partners, making it a valuable tool for studying DNA repair mechanisms, cell cycle dynamics, and oncogenic pathways. Researchers utilize recombinant PCLAF in *in vitro* assays, structural studies, and functional analyses to elucidate its role in carcinogenesis and therapeutic resistance.
Additionally, PCLAF has emerged as a potential therapeutic target. Inhibiting its activity or expression may suppress cancer cell proliferation and enhance the efficacy of DNA-damaging therapies like chemotherapy or radiation. The development of recombinant PCLAF also aids in antibody production for diagnostic applications, enabling the detection of PCLAF overexpression in clinical samples. Overall, PCLAF recombinant protein serves as a crucial resource for advancing both basic research and translational studies in oncology and molecular biology.
×
